Opening soon. Stay in the loop

goodmorrowJoin the opening list

Bremelanotide, explained.

PT-141 (Vyleesi). Research, safety questions, and treatment context.

Updated Clinical review pending · Educational draft

The form

More than one catalog form

The routine

The approved injection is used as needed.

The evidence

Large human trials for a specific injectable use

Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.

Legal status
FDA-approved drug

FDA-approved in 2019 as Vyleesi for premenopausal women with low sexual desire. Use in men is off-label.

At Goodmorrow
Offered when we open

What it is

Bremelanotide activates melanocortin receptors in the brain that are involved in sexual desire. Vyleesi is a small injection you give yourself about 45 minutes before sex, as needed.

What the evidence shows

In the trials behind its approval, women taking it reported a modest increase in desire and less distress about low desire compared with placebo. Evidence in men comes from earlier, smaller studies.

How Goodmorrow handles it

We check your blood pressure and history first, then prescribe the FDA-approved product.

Before you take it

  • Nausea is common, especially the first time. It briefly raises blood pressure, so it isn't for people with uncontrolled high blood pressure or heart disease.
  • The label limits it to one dose in 24 hours and eight doses a month. Some people notice darkening of the skin in small patches with repeated use.

Questions people ask

Does PT-141 work for men?

Vyleesi is approved for women. Men use it off-label, and the evidence comes from earlier, smaller studies. It acts on desire, not erections, so it's a different tool from Viagra or Cialis.

Sources

  1. FDA documentVyleesi (bremelanotide injection) prescribing information U.S. Food and Drug Administration, 2019

Good days ahead.

Join the opening list for appointment updates.

Join the opening list